A novel μ-oxo-diruthenium(III,III)-ibuprofen-(4-aminopyridine) chloride derived from the diruthenium(II,III)-ibuprofen paddlewheel metallodrug shows anticancer properties.

[1]  P. Sadler,et al.  Metallodrugs are unique: opportunities and challenges of discovery and development , 2020, Chemical science.

[2]  X. Wu,et al.  Synthesis of terpolymer-lipid encapsulated diruthenium(II,III)-anti-inflammatory metallodrug nanoparticles to enhance activity against glioblastoma cancer cells. , 2019, Journal of inorganic biochemistry.

[3]  M. Sanson,et al.  Temporary blood–brain barrier disruption by low intensity pulsed ultrasound increases carboplatin delivery and efficacy in preclinical models of glioblastoma , 2019, Journal of Neuro-Oncology.

[4]  V. Brabec,et al.  Ruthenium coordination compounds of biological and biomedical significance. DNA binding agents , 2018, Coordination Chemistry Reviews.

[5]  A. Lazcano,et al.  Structure, function and evolution of the hemerythrin‐like domain superfamily , 2018, Protein science : a publication of the Protein Society.

[6]  Weiling Li,et al.  Voltage-gated potassium channel blocker 4-aminopyridine induces glioma cell apoptosis by reducing expression of microRNA-10b-5p , 2018, Molecular biology of the cell.

[7]  Zhe-Sheng Chen,et al.  The development of anticancer ruthenium(ii) complexes: from single molecule compounds to nanomaterials. , 2017, Chemical Society reviews.

[8]  X. Wu,et al.  Diruthenium(ii,iii) metallodrugs of ibuprofen and naproxen encapsulated in intravenously injectable polymer-lipid nanoparticles exhibit enhanced activity against breast and prostate cancer cells. , 2017, Nanoscale.

[9]  A. Colquhoun,et al.  Axially-modified paddlewheel diruthenium(II,III)-ibuprofenato metallodrugs and the influence of the structural modification on U87MG and A172 human glioma cell proliferation, apoptosis, mitosis and migration. , 2016, Journal of inorganic biochemistry.

[10]  S. Nikolaou,et al.  Novel binuclear μ-oxo diruthenium complexes combined with ibuprofen and ketoprofen: Interaction with relevant target biomolecules and anti-allergic potential. , 2015, Journal of inorganic biochemistry.

[11]  Rute Nazaré Fernandes Sanches,et al.  Spectroscopic studies on interactions of the tetrakis(acetato)chloridodiruthenium(II,III) complex and the Ru2(II,III)-NSAID-derived metallodrugs of ibuprofen and ketoprofen with human serum albumin , 2015 .

[12]  D. O. Silva.  Ruthenium Compounds Targeting Cancer Therapy , 2014 .

[13]  Lily Yeh Jan,et al.  Targeting potassium channels in cancer , 2014, The Journal of cell biology.

[14]  A. Merlino,et al.  Unusual structural features in the lysozyme derivative of the tetrakis(acetato)chloridodiruthenium(II,III) complex. , 2014, Angewandte Chemie.

[15]  A. Colquhoun,et al.  Growth inhibitory effects of the Diruthenium-Ibuprofen compound, [Ru2Cl(Ibp)4], in human glioma cells in vitro and in the rat C6 orthotopic glioma in vivo , 2014, JBIC Journal of Biological Inorganic Chemistry.

[16]  L. Pardo,et al.  The roles of K+ channels in cancer , 2013, Nature Reviews Cancer.

[17]  R. van Eldik,et al.  Kinetic and mechanistic studies on reactions of diruthenium(II,III) with biologically relevant reducing agents. , 2013, Dalton transactions.

[18]  G. Javadi,et al.  Cisplatin downregulates BCL2L12, a novel apoptosis-related gene, in glioblastoma cells , 2013, In Vitro Cellular & Developmental Biology - Animal.

[19]  A. Bergamo,et al.  Synthesis and characterization of a diruthenium(II,III)–ketoprofen compound and study of the in vitro effects on CRC cells in comparison to the naproxen and ibuprofen derivatives , 2012 .

[20]  R. van Eldik,et al.  Thermodynamics of axial substitution and kinetics of reactions with amino acids for the paddlewheel complex tetrakis(acetato)chloridodiruthenium(II,III). , 2012, Inorganic chemistry.

[21]  A. Colquhoun,et al.  Inhibition of C6 rat glioma proliferation by [Ru2Cl(Ibp)4] depends on changes in p21, p27, Bax/Bcl2 ratio and mitochondrial membrane potential. , 2010, Journal of inorganic biochemistry.

[22]  D. O. Silva.  Perspectives for novel mixed diruthenium-organic drugs as metallopharmaceuticals in cancer therapy. , 2010, Anti-cancer agents in medicinal chemistry.

[23]  Geise Ribeiro,et al.  The novel ruthenium—γ‐linolenic complex [Ru2(aGLA)4Cl] inhibits C6 rat glioma cell proliferation and induces changes in mitochondrial membrane potential, increased reactive oxygen species generation and apoptosis in vitro , 2010, Cell biochemistry and function.

[24]  R. Shukla,et al.  Substitution of trans ligands in μ-oxo-bis(μ-acetato)diruthenium(III) complexes: Synthesis and kinetic studies , 2009 .

[25]  A. Roitberg,et al.  Theoretical and experimental studies of diruthenium tetracarboxylates structure, spectroscopy, and electrochemistry. , 2008, Inorganic chemistry.

[26]  Geise Ribeiro,et al.  Diruthenium(II, III) complexes of ibuprofen, aspirin, naproxen and indomethacin non-steroidal anti-inflammatory drugs: Synthesis, characterization and their effects on tumor-cell proliferation , 2008 .

[27]  G. Tamasi,et al.  A molecular orbital study of C–H···Cl– and N–H···Cl– hydrogen bonds. Inferences on selected metal complexes and on protein ClC Cl– channels , 2005 .

[28]  A. Lough,et al.  Redetermination of para-amino­pyridine (fampridine, EL-970) at 150 K , 2005 .

[29]  K. Hayes.  The use of 4-aminopyridine (fampridine) in demyelinating disorders. , 2006, CNS drug reviews.

[30]  J. D. Figueroa-Villar,et al.  NMR study of the leaving ligand and solvent effects on the solvolysis of (μ-oxo)bis(μ-acetato)diruthenium(III) complexes , 2004 .

[31]  S. Akyuz,et al.  Theoretical and experimental studies of IR spectra of 4-aminopyridine metal(II) complexes , 2003 .

[32]  Benjamin F. Gherman,et al.  How iron-containing proteins control dioxygen chemistry: a detailed atomic level description via accurate quantum chemical and mixed quantum mechanics/molecular mechanics calculations , 2003 .

[33]  M. Abe,et al.  A kinetic study on pyridine exchange reactions at a bis(μ-acetato)(μ-oxo)diruthenium(III) center: effects of monodentate and bidentate N-heterocyclic ligands cis to the oxo bridge , 2002 .

[34]  S. Bayari,et al.  Normal coordinate analysis of 4-aminopyridine. Effect of substituent on pyridine ring in metal complexes of 4-substituted pyridines. , 2001, Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy.

[35]  D. de Oliveira Silva,et al.  Synthesis and characterization of a diruthenium-ibuprofenato complex comparing its anti-inflammatory activity with that of a copper(II)-ibuprofenato complex. , 2000, Journal of inorganic biochemistry.

[36]  T. S. Cameron,et al.  Synthesis, structure and electrochemistry of nitrogen base adducts of tetraacetatodiruthenium(II,III): dependence of redox potential and Ru–Ru bond length on axial ligand donor strength , 2000 .

[37]  Y. Sasaki,et al.  Preparation and properties of a series of (μ-oxo)di(μ-acetato) diruthenium(III) complexes, [Ru2(μ-O)(μ-CH3COO)2(pyridine)4(L)2]2+ and [Ru2(μ-O)(μ-CH3COO)2(AA)2(L)2]2+, where AA is 2,2′-bipyridine or 1,10-phenanthroline, and L is a monodentate ligand , 1998 .

[38]  M. A. Aquino.  Diruthenium and diosmium tetracarboxylates: synthesis, physical properties and applications , 1998 .

[39]  C. Sudha,et al.  Synthesis, X-ray structures, and spectroscopic and electrochemical properties of (μ-oxo)bis(μ-carboxylato)diruthenium complexes having six imidazole bases as terminal ligands , 1998 .

[40]  J. Simard,et al.  4‐aminopyridine causes apoptosis and blocks an outward rectifier K+ channel in malignant astrocytoma cell lines , 1997, Journal of neuroscience research.

[41]  W. Wonderlin,et al.  Potassium Channels, Proliferation and G1 Progression , 1996, The Journal of Membrane Biology.

[42]  G. Christou,et al.  N7, O6 bridging 9-ethylguanine (9-EtGH) groups in dinuclear metal–metal bonded complexes with bond orders of one, two or four , 1996 .

[43]  G. Christou,et al.  Structural Evidence for a New Metal-Binding Mode for Guanine Bases: Implications for the Binding of Dinuclear Antitumor Agents to DNA , 1994 .

[44]  Tasuku Ito,et al.  Preparation, Structure, and Properties of the Bis(μ-acetato)(μ-oxo)Ruthenium(III) Dimers [Ru2(μ-CH3COO)2(μ-O)(py)6]2+ and [Ru2(μ-CH3COO)2(μ-O)(bpy)2(py)2]2+ , 1991 .

[45]  K. Wieghardt,et al.  (.mu.-Hydroxo)bis(.mu.-carboxylato)diruthenium and (.mu.-oxo)bis(.mu.-carboxylato)diruthenium Complexes Containing Weatk Intramolecular Ru.cntdot..cntdot..cntdot.Ru interactions , 1989 .

[46]  M. Henn,et al.  New Ruthenium Complexes for the Treatment of Cancer , 1989 .

[47]  H. Toma,et al.  Redox potentials of trinuclear μ-oxo ruthenium acetate clusters with N-heterocyclic ligands , 1988 .

[48]  H. Taube,et al.  Properties of (4-aminopyridine)pentaammineruthenium(II) and -(III) , 1981 .

[49]  W. Geary.  The use of conductivity measurements in organic solvents for the characterisation of coordination compounds , 1971 .